Serum NRG4 levels are decreased in patients with non-alcoholic fatty liver, acute coronary syndrome, and metabolic disorders compared to control groups [52,53,54], and upregulation of NRG4 attenuates insulin resistance and decreases hepatic steatosis [55,56]. This evidence concerns the gene NRG4 and fatty liver disease.